QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

Scale your comprehensive genomic profiling workflow with superior automated variant interpretation

June 22, 2023 @ 11:00 am - 12:30 pm

Automating and scaling a comprehensive genomic profiling workflow can be a tedious and challenging process that requires lots of time and resources. However, an intelligent clinical decision support platform and on-demand expert support services can make all the difference.

In this webinar, learn about QIAGEN Clinical Insight (QCI) Interpret for Oncology, a clinical decision support platform that has been trusted to analyze and interpret more than 3 million patient molecular profiles worldwide. Unlike other commercial solutions, QCI Interpret for Oncology is powered by augmented molecular intelligence and offers in-software access to a team of variant scientists to assist you with rare or novel variant research, curation, and interpretation. The platform connects to the QIAGEN Knowledge Base—the highest quality genomic knowledge base in the industry—and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines. To help you further scale and reduce hands-on time, QCI Interpret for Oncology provides over 410,000 variant interpretation summaries that have all been reviewed by oncologists. This enables you to quickly build custom reports for your oncologists and their patients with the latest diagnostic and prognostic information, as well as biomarker-directed therapy and clinical trial recommendations.

By attending this webinar, you will:

Receive a step-by-step guide of how to go from VCF to final report using QCI Interpret for Oncology
Learn about the platform’s automated variant classification process
Learn how QIAGEN uses augmented molecular intelligence to enhance our expert curation process
See first-hand how to build a custom report with an opportunity to submit your own VCF file for a sample report

On-demand Webinars


  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...